ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$1.76 USD
-0.06 (-3.30%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.77 +0.01 (0.57%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth C Momentum F VGM
ProQR (PRQR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.88 | $6.00 | $2.50 | 168.13% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for ProQR comes to $4.88. The forecasts range from a low of $2.50 to a high of $6.00. The average price target represents an increase of 168.13% from the last closing price of $1.82.
Analyst Price Targets (4 )
Broker Rating
ProQR currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/11/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
8/8/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
4/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/8/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/8/2024 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
1/24/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 6 |
Average Target Price | $4.88 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -0.12 |
PRQR FAQs
ProQR Therapeutics N.V. (PRQR) currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for ProQR Therapeutics N.V. (PRQR) is $4.88. The current on short-term price targets is based on 4 reports.
The forecasts for ProQR Therapeutics N.V. (PRQR) range from a low of $2.5 to a high of $6. The average price target represents a increase of $177.27 from the last closing price of $1.76.
The current UPSIDE for ProQR Therapeutics N.V. (PRQR) is 177.27%
Based on short-term price targets offered by four analysts, the average price target for ProQR comes to $4.88. The forecasts range from a low of $2.50 to a high of $6.00. The average price target represents an increase of 168.13% from the last closing price of $1.82.